Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial

References

• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD. GOLD; 2021. Available from: https://goldcopd.org. Accessed January 6, 2022.
   Google Scholar
• Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004;200(5):689–695. doi:10.1084/jem.20040416
   PubMed Web of Science ®Google Scholar
• Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352(19):1967–1976. doi:10.1056/NEJMoa041892
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol. 2009;71(1):451–464. doi:10.1146/annurev.physiol.010908.163257
   PubMed Web of Science ®Google Scholar
• Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax. 2009;64(5):424–429. doi:10.1136/thx.2008.103432
   PubMed Web of Science ®Google Scholar
• Devereux G, Cotton S, Fielding S, et al. Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial. JAMA. 2018;320(15):1548–1559. doi:10.1001/jama.2018.14432
   PubMed Web of Science ®Google Scholar
• Jenkins CR, Wen F-Q, Martin A, et al. The effect of low dose corticosteroids and Theophylline on the risk of acute exacerbations of COPD. The TASCS randomised controlled trial. Eur Respir J. 2020;57:2003338.
   Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi:10.1016/S2213-2600(18)30006-7
   PubMed Web of Science ®Google Scholar
• Barnes NC, Sharma R, Lettis S, Calverley PMA. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47(5):1374. doi:10.1183/13993003.01370-2015
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-8
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine Beclomethasone/Formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–525. doi:10.1164/rccm.201502-0235LE
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-5
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398. doi:10.1016/S2213-2600(16)00100-4
   PubMed Web of Science ®Google Scholar
• Cheng S-L, Lin C-H. COPD guidelines in the Asia-pacific regions: similarities and differences. Diagnostics. 2021;11(7):1153. doi:10.3390/diagnostics11071153
   Web of Science ®Google Scholar
• Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society; Chronic Obstructive Pulmonary Disease Committee of Chinese Association of Chest Physicians. [Guidelines for diagnosis and treatment of Chronic Obstructive Pulmonary Disease (2021 Revised Edition)]. Chin J Tuberc Respir Dis. 2021;44(3):170–205. doi:10.3760/cma.j.cn112147-20210109-00031
   Google Scholar
• Bao H, Jia G, Cong S, et al. Phenotype and management of chronic obstructive pulmonary disease patients in general population in China: a nationally cross-sectional study. NPJ Prim Care Respir Med. 2021;31(1):32. doi:10.1038/s41533-021-00243-x
   PubMed Web of Science ®Google Scholar
• Lou P, Zhu Y, Chen P, et al. Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study. BMC Public Health. 2012;12(1):287. doi:10.1186/1471-2458-12-287
   PubMed Web of Science ®Google Scholar
• Wu HX, Zhuo KQ, Cheng DY. Peripheral blood eosinophil as a biomarker in outcomes of acute exacerbation of Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2019;14:3003–3015. doi:10.2147/COPD.S226783
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liang L-R, Zhang S, et al. Blood eosinophilia and its stability in hospitalized COPD exacerbations are associated with lower risk of all-cause mortality. Int J Chron Obstruct Pulmon Dis. 2020;15:1123–1134. doi:10.2147/COPD.S245056
   PubMed Web of Science ®Google Scholar
• Zeng Q, Wang H, Wang K, Zhou H, Wang T, Wen F. Eosinophilic phenotype was associated with better early clinical remission in elderly patients but not middle-aged patients with acute exacerbations of COPD. Int J Clin Pract. 2021;75(9):e14415. doi:10.1111/ijcp.14415
   PubMed Web of Science ®Google Scholar
• Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037–47.e10. doi:10.1016/j.jaci.2018.04.010
   PubMed Web of Science ®Google Scholar
• Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956–967. doi:10.1016/S2213-2600(17)30432-0
   PubMed Web of Science ®Google Scholar
• DiSantostefano RL, Hinds D, Van Le H, Barnes NC. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort. Respir Med. 2016;112:88–96. doi:10.1016/j.rmed.2016.01.013
   PubMed Web of Science ®Google Scholar
• Zysman M, Deslee G, Caillaud D, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1819–1824. doi:10.2147/COPD.S129787
   PubMed Web of Science ®Google Scholar
• Kruis AL, Ställberg B, Jones RCM, et al. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One. 2014;9(3):e90145.
   PubMed Web of Science ®Google Scholar
• Shuai T, Zhang C, Zhang M, et al. Low-dose theophylline in addition to ICS therapy in COPD patients: a systematic review and meta-analysis. PLoS One. 2021;16(5):e0251348. doi:10.1371/journal.pone.0251348
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in Chronic Obstructive Pulmonary Disease (TORCH). N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• George MD, Baker JF, Winthrop K, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis. Ann Intern Med. 2020;173(11):870–878. doi:10.7326/M20-1594
   PubMed Web of Science ®Google Scholar
• Rhee CK, Chau NQ, Yunus F, Matsunaga K, Perng D-W. Management of COPD in Asia: a position statement of the Asian Pacific Society of Respirology. Respirology. 2019;24(10):1018–1025. doi:10.1111/resp.13633
   PubMed Web of Science ®Google Scholar
• Chen Y-D, Zhou C-H, Zhu -H-H, et al. National survey on the current status of important human parasitic diseases in China in 2015. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2020;38(1):5–12.
   Google Scholar
• Zheng J, Jian W, Su L, Xue W. Blood eosinophil levels in Chinese patients with Chronic Obstructive Pulmonary Disease: pooled analysis of 7 Phase 3/4 randomized controlled trials. B24 biomarkers in COPD. American Thoracic Society International Conference Abstracts: American Thoracic Society; 2020:A2853–A.
   Google Scholar
• Saiphoklang N, Chomchoey C. Eosinophilia and parasitic infestations in patients with chronic obstructive pulmonary disease. Sci Rep. 2020;10(1):12490. doi:10.1038/s41598-020-69541-7
   PubMed Web of Science ®Google Scholar
• Juthong S, Kaenmuang P. Association between blood eosinophils with exacerbation and patient-reported outcomes in chronic obstructive pulmonary disease patients in an endemic area for parasitic infections: a prospective study. J Thorac Dis. 2020;12(9):4868–4876. doi:10.21037/jtd-19-4101
   PubMed Web of Science ®Google Scholar